Chapter 1 Methodology and Scope
1.1 Market segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.3.6 List of Primary Sources
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Abbreviations
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.11.3 Objective 3
1.11.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Snapshot
Chapter 3 Market Variables, Trends, & Scope
3.1 Parent Market
3.1.1 Europe Branded Generics Market
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Landscape
3.4 Europe Branded Generics Market Dynamics
3.4.1 Market Driver Analysis
3.4.1.1 Patent expiry of branded products
3.4.1.2 Increasing marketing approval and launch of branded generic products
3.4.1.3 Increasing disease burden and rising geriatric population
3.4.2 Market Restraint Analysis
3.4.2.1 Pricing pressure
3.4.3 Market Opportunity Analysis
3.4.3.1 Government initiatives promoting usage of generics
3.5 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.6 Porter’s Five Forces Analysis
Chapter 4 Europe Branded Generics Market - Segment Analysis, By Drug Class, 2018 - 2030 (USD Million)
4.1 Europe Branded Generics Market: Drug Class Movement Analysis
4.2 Alkylating Agents
4.2.1 Alkylating Agents Market Estimates and Forecast, 2018 - 2030 (USD Million)
4.3 Antimetabolites
4.3.1 Antimetabolites Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4 Hormones
4.4.1 Hormones Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5 Anti-hypertensive & Lipid lowering drugs
4.5.1 Anti-hypertensive & lipid lowering drugs market estimates and forecasts, 2018 - 2030 (USD Million)
4.6 Anti-depressants
4.6.1 Anti-depressants Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.7 Anti-psychotics
4.7.1 Anti-Psychotics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.8 Anti-epileptics
4.8.1 Anti-epileptics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
4.9 Others
4.9.1 Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5 Europe Branded Generics Market: Segment Analysis, by Application, 2018 - 2030 (USD Million)
5.1 Europe Branded Generics Market: Application Movement Analysis
5.2 Oncology
5.2.1 Oncology Market Estimates and Forecast, 2018 - 2030 (USD Million)
5.3 cardiovascular diseases
5.3.1 Cardiovascular Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
5.4 Neurological Diseases
5.4.1 Neurological Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
5.5 Acute and Chronic Pain
5.5.1 Acute and Chronic Pain Market Estimates and Forecast, 2018 - 2030 (USD Million)
5.6 Gastrointestinal Diseases
5.6.1 Gastrointestinal Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
5.7 Dermatological Diseases
5.7.1 Dermatological Diseases Market Estimates and Forecast, 2018 - 2030 (USD Million)
5.8 Others
5.8.1 Others Market Estimates and Forecast, 2018-2030 (USD Million)
Chapter 6 Europe Branded Generics Market: Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)
6.1 Europe Branded Generics Market: Route of Administration Movement Analysis
6.2 Topical
6.2.1 Topical Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.3 Oral
6.3.1 Oral Market Estimates and Forecast, 2018 - 2030 (USD Million)
6.4 Parenteral
6.4.1 Parenteral Market Estimates and Forecast, 2018-2030 (USD Million)
6.5 Others
6.5.1 Others Market Estimates and Forecast, 2018 - 2030 (USD Million)
Chapter 7 Europe Branded Generics Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)
7.1 Europe Branded Generics Market: Distribution Channel Movement Analysis
7.2 Hospital Pharmacy
7.2.1 Hospital Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
7.3 Retail Pharmacy
7.3.1 Retail Pharmacy Market Estimates and Forecast, 2018-2030 (USD Million)
7.4 Online Pharmacy
7.4.1 Online Pharmacy Market Estimates and Forecast, 2018 - 2030 (USD Million)
Chapter 8 Europe Branded Generics Market: Regional Estimates and Trend Analysis, by Drug Class, Application, Route of Administration, & Distribution Channel
8.1 Europe
8.1.1 SWOT Analysis:
8.1.1.1 Europe Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.1.2 Germany
8.1.2.1 Key Country Dynamics
8.1.2.2 Target Disease Prevalence
8.1.2.3 Competitive Scenario
8.1.2.4 Regulatory Framework
8.1.2.5 Reimbursement Scenario
8.1.2.6 Prescription and Dispensing Scenario
8.1.2.7 Germany Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.1.3 UK
8.1.3.1 Key Country Dynamics
8.1.3.2 Target Disease Prevalence
8.1.3.3 Competitive Scenario
8.1.3.4 Regulatory Framework
8.1.3.5 Reimbursement Scenario
8.1.3.6 UK Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.1.4 France
8.1.4.1 Key Country Dynamics
8.1.4.2 Target Disease Prevalence
8.1.4.3 Competitive Scenario
8.1.4.4 Regulatory Framework
8.1.4.5 Reimbursement Scenario
8.1.4.6 France Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.1.5 Italy
8.1.5.1 Key Country Dynamics
8.1.5.2 Target Disease Prevalence
8.1.5.3 Competitive Scenario
8.1.5.4 Regulatory Framework
8.1.5.5 Reimbursement Scenario
8.1.5.6 Italy Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.1.6 Spain
8.1.6.1 Key Country Dynamics
8.1.6.2 Target Disease Prevalence
8.1.6.3 Competitive Scenario
8.1.6.4 Regulatory Framework
8.1.6.5 Reimbursement Scenario
8.1.6.6 Spain Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.1.7 Russia
8.1.7.1 Key Country Dynamics
8.1.7.2 Target Disease Prevalence
8.1.7.3 Competitive Scenario
8.1.7.4 Regulatory Framework
8.1.7.5 Reimbursement Scenario
8.1.7.6 Russia Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.1.8 Denmark
8.1.8.1 Key Country Dynamics
8.1.8.2 Target Disease Prevalence
8.1.8.3 Competitive Scenario
8.1.8.4 Regulatory Framework
8.1.8.5 Reimbursement Scenario
8.1.8.6 Denmark Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.1.9 Sweden
8.1.9.1 Key Country Dynamics
8.1.9.2 Target Disease Prevalence
8.1.9.3 Competitive Scenario
8.1.9.4 Regulatory Framework
8.1.9.5 Reimbursement Scenario
8.1.9.6 Sweden Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.1.10 Norway
8.1.10.1 Key Country Dynamics
8.1.10.2 Target Disease Prevalence
8.1.10.3 Competitive Scenario
8.1.10.4 Regulatory Framework
8.1.10.5 Reimbursement Scenario
8.1.10.6 Norway Branded Generics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
8.1.11 Rest of Europe
Chapter 9 Europe Branded Generics Market: - Competitive Landscape
9.1 Recent Developments & Impact Analysis, by Key Market Participants
9.1.1 New Product Launch
9.1.2 Merger and Acquisition
9.1.3 Licensing Agreements
9.1.4 Conferences and Campaigns
9.2 Company Categorization
9.2.1 Innovators
9.2.2 Market Leaders
9.3 Vendor Landscape
9.3.1 List of key distributors and channel partners
9.3.2 Key customers
9.4 Public Companies
9.4.1 Key company market share analysis, 2021
9.4.2 Company market position analysis
9.4.3 Heat map analysis
9.4.4 Competitive Dashboard Analysis
9.4.4.1 Market Differentiators
9.5 Private Companies
9.5.1 List of key emerging companies
9.5.2 Regional Network Map
9.6 Company Profiles
9.6.1 Teva Pharmaceutical Industries Ltd.
9.6.1.1 Company overview
9.6.1.2 Financial performance
9.6.1.3 Product benchmarking
9.6.1.4 Strategic initiatives
9.6.2 LUPIN
9.6.2.1 Company overview
9.6.2.2 Financial performance
9.6.2.3 Product benchmarking
9.6.2.4 Strategic initiatives
9.6.3 Sanofi
9.6.3.1 Company overview
9.6.3.2 Financial performance
9.6.3.3 Product benchmarking
9.6.3.4 Strategic initiatives
9.6.4 Sun Pharmaceutical Industries Ltd.
9.6.4.1 Company overview
9.6.4.2 Financial performance
9.6.4.3 Product benchmarking
9.6.4.4 Strategic initiatives
9.6.5 Dr. Reddy’s Laboratories Ltd.
9.6.5.1 Company Overview
9.6.5.2 Financial Performance
9.6.5.3 Product benchmarking
9.6.5.4 Strategic initiatives
9.6.6 Endo International plc
9.6.6.1 Company overview
9.6.6.2 Financial performance
9.6.6.3 Product benchmarking
9.6.6.4 Strategic initiatives
9.6.7 GlaxoSmithKline Plc
9.6.7.1 Company Overview
9.6.7.2 Financial Performance
9.6.7.3 Product Benchmarking
9.6.7.4 Strategic Initiatives
9.6.8 Wockhardt
9.6.8.1 Company overview
9.6.8.2 Financial Performance
9.6.8.3 Product benchmarking
9.6.8.4 Strategic initiatives
9.6.9 Viatris, Inc.
9.6.9.1 Company Overview
9.6.9.2 Financial Performance
9.6.9.3 Product Benchmarking
9.6.9.4 Strategic Initiatives
9.6.10 Apotex, Inc.
9.6.10.1 Company overview
9.6.10.2 Product benchmarking
9.6.10.3 Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviation
Table 3 Regulatory framework
Table 4 Patent expiry of branded products
Table 5 Healthcare expenses on pharmaceuticals
Table 6 List of branded generic oral hormone products
Table 7 List of generic anti-hypertensive products
Table 8 Estimated new cancer case statistics 2020
Table 9 Prevalence of GERD
Table 10 List of topical branded generics
Table 11 List of select oral branded generics from Cipla
Table 12 Pharmacy density across major Europe countries
Table 13 Europe branded generics market, company market share analysis, 2022
Table 14 Key companies adopting expansion strategy
Table 15 Key companies adopting acquisition strategy
Table 16 Key companies adopting collaboration strategy
Table 17 Key companies launching new products/services
Table 18 Key companies adopting partnership strategy
Table 19 Key Companies undergoing Other Strategies
Table 20 Europe branded generics Market, by country, 2018 - 2030 (USD Million)
Table 21 Europe branded generics market, by drug class, 2018 - 2030 (USD Million)
Table 22 Europe branded generics Market, by application, 2018 - 2030 (USD Million)
Table 23 Europe branded generics Market, by route of administration, 2018 - 2030 (USD Million)
Table 24 Europe branded generics market, by distribution channel, 2018 - 2030 (USD Million)
Table 25 Germany branded generics market, by drug class, 2018 - 2030 (USD Million)
Table 26 Germany branded generics market, by application, 2018 - 2030 (USD Million)
Table 27 Germany branded generics market, by route of administration, 2018 - 2030 (USD Million)
Table 28 Germany branded generics market, by distribution channel, 2018 - 2030 (USD Million)
Table 29 UK branded generics market, by drug class, 2018 - 2030 (USD Million)
Table 30 UK branded generics market, by application, 2018 - 2030 (USD Million)
Table 31 UK branded generics market, by route of administration, 2018 - 2030 (USD Million)
Table 32 UK branded Generics Market, by distribution channel, 2018 - 2030 (USD Million)
Table 33 France branded generics market, by drug class, 2018 - 2030 (USD Million)
Table 34 France branded generics market, by application, 2018 - 2030 (USD Million)
Table 35 France branded generics market, by route of administration, 2018 - 2030 (USD Million)
Table 36 France branded generics market, by distribution channel, 2018 - 2030 (USD Million)
Table 37 Italy branded generics market, by drug class, 2018 - 2030 (USD Million)
Table 38 Italy branded generics market, by application, 2018 - 2030 (USD Million)
Table 39 Italy branded generics market, by route of administration, 2018 - 2030 (USD Million)
Table 40 Italy branded generics market, by distribution channel, 2018 - 2030 (USD Million)
Table 41 Spain branded generics market, by drug class, 2018 - 2030 (USD Million)
Table 42 Spain branded generics market, by application, 2018 - 2030 (USD Million)
Table 43 Spain branded generics market, by route of administration, 2018 - 2030 (USD Million)
Table 44 Spain branded generics market, by distribution channel, 2018 - 2030 (USD Million)
Table 45 Russia branded generics market, by drug class, 2018 - 2030 (USD Million)
Table 46 Russia branded generics market, by application, 2018 - 2030 (USD Million)
Table 47 Russia branded generics market, by route of administration, 2018 - 2030 (USD Million)
Table 48 Russia branded generics market, by distribution channel, 2018 - 2030 (USD Million)
Table 49 Sweden branded generics market, by drug class, 2018 - 2030 (USD Million)
Table 50 Sweden branded generics market, by application, 2018 - 2030 (USD Million)
Table 51 Sweden branded generics market, by route of administration, 2018 - 2030 (USD Million)
Table 52 Sweden branded generics market, by distribution channel, 2018 - 2030 (USD Million)
Table 53 Denmark branded generics market, by drug class, 2018 - 2030 (USD Million)
Table 54 Denmark branded generics market, by application, 2018 - 2030 (USD Million)
Table 55 Denmark branded generics market, by route of administration, 2018 - 2030 (USD Million)
Table 56 Denmark branded generics market, by distribution channel, 2018 - 2030 (USD Million)
Table 57 Norway branded generics market, by drug class, 2018 - 2030 (USD Million)
Table 58 Norway branded generics market, by application, 2018 - 2030 (USD Million)
Table 59 Norway branded generics market, by route of administration, 2018 - 2030 (USD Million)
Table 60 Norway branded generics market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
FIG. 1 Europe branded generics market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Commodity Flow Analysis
Fig. 10 Market snapshot (2022) (USD Million)
Fig. 11 Segment snapshot (2022) (USD Million)
Fig. 12 Segment snapshot (2022) (USD Million)
Fig. 13 Competitive snapshot
Fig. 14 Penetration and growth prospect mapping
Fig. 15 Europe branded generics market driver impact
Fig. 16 Europe branded generics market restraint impact
Fig. 17 SWOT analysis, by factor (Political & Legal, Economic, and Technological)
Fig. 18 Porter’s Five Forces Analysis
Fig. 19 Europe branded generics market: Drug class outlook and key takeaways
Fig. 20 Europe branded generics market: Drug class movement analysis
Fig. 21 Alkylating agents market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Antimetabolites market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Hormones market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Anti-hypertensive & lipid lowering drugs market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Anti-depressants market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Anti-psychotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Anti-epileptics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Europe branded generics market: Application outlook and key takeaways
Fig. 30 Europe branded generics market: Application movement analysis
Fig. 31 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Cardiovascular diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Neurological and psychiatric diseases cases in Millions
Fig. 34 Neurological diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Acute and chronic pain market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Gastrointestinal diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Dermatological diseases market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Europe branded generics market: Route of administration outlook and key takeaways
Fig. 40 Europe branded generics market: Route of administration movement analysis
Fig. 41 Topical market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Oral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Europe branded generics market: Distribution channel outlook and key takeaways
Fig. 46 Europe branded generics Market: Distribution Channel Movement Analysis
Fig. 47 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 50 Regional marketplace: Key takeaways
Fig. 51 Europe: SWOT analysis
Fig. 52 Europe branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Germany country dynamics
Fig. 54 GermanyTarget disease prevalence (Patient Volume) ('000), 2018 - 2030
Fig. 55 Germany branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 UK country dynamics
Fig. 57 Uk Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 58 UK branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 France Key country dynamics
Fig. 60 France Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 61 France branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Italy Key country dynamics
Fig. 63 Italy Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 64 Italy branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Spain Key country dynamics
Fig. 66 Spain Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 67 Spain branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Russia Key country dynamics
Fig. 69 Russia Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 70 Russia branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Denmark Key country dynamics
Fig. 72 Denmark Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 73 Denmark branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 74 Sweden Key country dynamics
Fig. 75 Sweden Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 76 Sweden branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Norway Key country dynamics
Fig. 78 Norway Target disease prevalence (Patient volume) ('000), 2018 - 2030
Fig. 79 Norway branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Rest of Europe branded generics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Heat map analysis
Fig. 82 Strategic framework
